{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:13:04Z","timestamp":1793326384110,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.prostaglandins.2020.106477","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T21:19:31Z","timestamp":1595452771000},"page":"106477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Dysregulated metabolism of polyunsaturated fatty acids in eosinophilic allergic diseases"],"prefix":"10.1016","volume":"150","author":[{"given":"Jun","family":"Miyata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prostaglandins.2020.106477_bib0005","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0015","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1365-2222.1999.00447.x","article-title":"The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma","volume":"29","author":"Diamant","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1164\/ajrccm.161.6.9907054","article-title":"Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals","volume":"161","author":"Lee","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1067\/mai.2002.124269","article-title":"Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils","volume":"109","author":"Bandeira-Melo","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.12.958","article-title":"Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines","volume":"140","author":"Salimi","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1084\/jem.20020044","article-title":"Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists","volume":"195","author":"Mellor","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0045","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1073\/pnas.141221498","article-title":"Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells","volume":"98","author":"Mellor","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaci.2005.03.014","article-title":"Expression of functional cysteinyl leukotriene receptors by human basophils","volume":"116","author":"Gauvreau","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1067\/mai.2002.122841","article-title":"Leukotriene D4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor","volume":"109","author":"Nagata","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1081-1206(10)61269-0","article-title":"Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin","volume":"93","author":"Saito","year":"2004","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.alit.2019.06.002","article-title":"Cysteinyl leukotriene metabolism of human eosinophils in allergic disease","volume":"69","author":"Miyata","year":"2020","journal-title":"Allergol. Int."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2012.07.048","article-title":"Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma","volume":"131","author":"Miyata","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.alit.2014.08.003","article-title":"Role of omega-3 fatty acids and their metabolites in asthma and allergic diseases","volume":"64","author":"Miyata","year":"2015","journal-title":"Allergol. Int."},{"issue":"Suppl","key":"10.1016\/j.prostaglandins.2020.106477_bib0080","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.alit.2016.05.010","article-title":"Eosinophil polyunsaturated fatty acid metabolism and its potential control of inflammation and allergy","volume":"65","author":"Arita","year":"2016","journal-title":"Allergol. Int."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2014.08.014","article-title":"Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge","volume":"135","author":"Takeda","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0090","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0095","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1096\/fj.10-170027","article-title":"Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice","volume":"25","author":"Yamada","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0100","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/gutjnl-2014-306998","article-title":"Eosinophil-mediated signalling attenuates inflammatory responses in experimental colitis","volume":"64","author":"Masterson","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0105","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0110","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1172\/JCI97945","article-title":"Leukotriene biosynthetic enzymes as therapeutic targets","volume":"128","author":"Haeggstrom","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0115","doi-asserted-by":"crossref","first-page":"28277","DOI":"10.1074\/jbc.273.43.28277","article-title":"Gamma-glutamyl leukotrienase, a gamma-glutamyl transpeptidase gene family member, is expressed primarily in spleen","volume":"273","author":"Carter","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)64204-6","article-title":"Gamma-glutamyl leukotrienase, a novel endothelial membrane protein, is specifically responsible for leukotriene D(4) formation in vivo","volume":"161","author":"Han","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1096\/fj.02-0899fje","article-title":"Identification of two additional members of the membrane-bound dipeptidase family","volume":"17","author":"Habib","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4168\/aair.2014.6.4.288","article-title":"Cysteinyl leukotrienes and their receptors; emerging concepts","volume":"6","author":"Kanaoka","year":"2014","journal-title":"Allergy Asthma Immunol. Res."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0135","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1172\/JCI97946","article-title":"Leukotriene receptors as potential therapeutic targets","volume":"128","author":"Yokomizo","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2147\/DDDT.S39100","article-title":"Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?","volume":"8","author":"Hon","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0145","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.resinv.2019.08.003","article-title":"Current state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma","volume":"57","author":"Yamamoto","year":"2019","journal-title":"Respir. Investig."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0150","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","article-title":"Proresolving lipid mediators and mechanisms in the resolution of acute inflammation","volume":"40","author":"Buckley","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0165","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0170","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1172\/JCI99888","article-title":"GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain","volume":"128","author":"Bang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0175","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1074\/jbc.M112.340612","article-title":"Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid","volume":"287","author":"Isobe","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jb\/mvs151","article-title":"Stereochemical assignment and anti-inflammatory properties of the omega-3 lipid mediator resolvin E3","volume":"153","author":"Isobe","year":"2013","journal-title":"J. Biochem."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0185","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1096\/fj.13-236224","article-title":"Eicosapentaenoic acid is converted via omega-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid","volume":"28","author":"Kubota","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/all.13297","article-title":"12-OH-17,18-Epoxyeicosatetraenoic acid alleviates eosinophilic airway inflammation in murine lungs","volume":"73","author":"Mochimaru","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000237697","article-title":"Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks","volume":"114","author":"Oosaki","year":"1997","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/thorax.2003.006825","article-title":"Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation","volume":"59","author":"Green","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0205","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1164\/rccm.200801-061OC","article-title":"Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma","volume":"178","author":"Planaguma","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0210","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0140-6736(89)91611-5","article-title":"Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis","volume":"1","author":"Taylor","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0215","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jaci.2008.06.009","article-title":"Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation","volume":"122","author":"Ono","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1164\/ajrccm.161.5.9906068","article-title":"Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics","volume":"161","author":"Macfarlane","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0225","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1378\/chest.120.6.1822","article-title":"Circadian characteristics of urinary leukotriene E(4) in healthy subjects and nocturnal asthmatic patients","volume":"120","author":"Kurokawa","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0230","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.124.5.1768","article-title":"High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma","volume":"124","author":"Tanaka","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1164\/ajrccm\/142.1.73","article-title":"Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma","volume":"142","author":"Pliss","year":"1990","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1164\/rccm.200412-1667OC","article-title":"Inflammatory basis of exercise-induced bronchoconstriction","volume":"172","author":"Hallstrand","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0245","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jaci.2015.10.009","article-title":"Chronic rhinosinusitis pathogenesis","volume":"136","author":"Stevens","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0250","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaci.2003.10.068","article-title":"Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis","volume":"113","author":"Higashi","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0260","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1164\/rccm.2101021","article-title":"Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma","volume":"166","author":"Antczak","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0265","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaip.2017.07.001","article-title":"Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma","volume":"6","author":"Bochenek","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0270","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2013.07.004","article-title":"Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis","volume":"133","author":"Bochenek","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0275","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-6749(99)70324-6","article-title":"Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses","volume":"104","author":"Daffern","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1164\/ajrccm.149.4.8143059","article-title":"Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge","volume":"149","author":"Sladek","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0285","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1378\/chest.121.1.143","article-title":"Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients","volume":"121","author":"Obase","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0290","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1365-2222.2004.02123.x","article-title":"Exhaled eicosanoids following oral aspirin challenge in asthmatic patients","volume":"34","author":"Sanak","year":"2004","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0295","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1067\/mai.2002.127001","article-title":"Characterization of PGE2 receptor subtypes in human eosinophils","volume":"110","author":"Mita","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0300","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm748","article-title":"Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4)","volume":"8","author":"Levy","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0305","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1096\/fj.07-8653com","article-title":"Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism","volume":"21","author":"Levy","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0310","first-page":"2","article-title":"ALX receptor ligands define a biochemical endotype for severe asthma","author":"Ricklefs","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0315","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1164\/rccm.200201-053OC","article-title":"Lipoxins are potential endogenous antiinflammatory mediators in asthma","volume":"165","author":"Bonnans","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaci.2004.09.038","article-title":"Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound","volume":"115","author":"Vachier","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0325","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaci.2013.01.058","article-title":"Exhaled breath condensate eicosanoid levels associate with asthma and its severity","volume":"132","author":"Kazani","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0330","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/6\/2\/026001","article-title":"Profile of eicosanoids in breath condensate in asthma and COPD","volume":"6","author":"Fritscher","year":"2012","journal-title":"J. Breath Res."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0335","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PCC.0b013e3182231644","article-title":"Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus","volume":"13","author":"Hasan","year":"2012","journal-title":"Pediatr. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02770900701847068","article-title":"The role of lipoxin A4 in exercise-induced bronchoconstriction in asthma","volume":"45","author":"Tahan","year":"2008","journal-title":"J. Asthma"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0345","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2011.03839.x","article-title":"Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0350","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","article-title":"Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions","volume":"92","author":"Cl\u00e0ria","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0355","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4049\/jimmunol.178.1.496","article-title":"Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness","volume":"178","author":"Levy","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0360","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1172\/JCI620","article-title":"Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma","volume":"101","author":"Cowburn","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0365","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1164\/ajrccm.164.11.2008137","article-title":"Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics","volume":"164","author":"Seymour","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0370","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1398-9995.1985.tb00884.x","article-title":"Increased generation of leukotriene C4 from eosinophils in asthmatic patients","volume":"40","author":"Taniguchi","year":"1985","journal-title":"Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0375","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000235025","article-title":"Enhanced leukotriene C4 production by peripheral eosinophilic granulocytes from children with asthma","volume":"90","author":"Schauer","year":"1989","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0380","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1992.tb04062.x","article-title":"Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects","volume":"33","author":"Sampson","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0385","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1183\/09031936.95.08091465","article-title":"Blood eosinophil leukotriene C4 production in asthma of different severities","volume":"8","author":"Laviolette","year":"1995","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0390","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/thx.51.2.155","article-title":"Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients","volume":"51","author":"Shindo","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0395","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1006\/bbrc.1998.8789","article-title":"Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics","volume":"247","author":"Koshino","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0400","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4049\/jimmunol.163.1.456","article-title":"IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils","volume":"163","author":"Cowburn","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0405","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/ajrcmb.23.3.4051","article-title":"Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma","volume":"23","author":"Sanak","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0410","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.1979","article-title":"Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma","volume":"209","author":"Adamjee","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0415","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0420","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1164\/rccm.200410-1413OC","article-title":"Diminished lipoxin biosynthesis in severe asthma","volume":"172","author":"Levy","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0425","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1365-2222.2007.02806.x","article-title":"Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity","volume":"37","author":"Celik","year":"2007","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0430","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ppul.21186","article-title":"Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree","volume":"45","author":"Wu","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0435","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1399-3003.2000.16a08.x","article-title":"Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics","volume":"16","author":"Sanak","year":"2000","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0440","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1465-9921-11-71","article-title":"Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma","volume":"11","author":"Bhavsar","year":"2010","journal-title":"Respir. Res."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0445","first-page":"301","article-title":"Proteogenomic analyses of cellular lysates using a phenol-guanidinium thiocyanate reagent","volume":"18","author":"Kawashima","year":"2019","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0450","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/all.13726","article-title":"Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis","volume":"74","author":"Miyata","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0455","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.01.019","article-title":"Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation","volume":"139","author":"Gevaert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0465","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0470","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0475","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0480","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.prostaglandins.2020.106477_bib0485","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:01:59Z","timestamp":1761098519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882320300708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":97,"alternative-id":["S1098882320300708"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106477","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulated metabolism of polyunsaturated fatty acids in eosinophilic allergic diseases","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106477"}}